BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT UID:53d3a2bc0b4c1eebbd160b3ae0958701 CATEGORIES:Colloquium CREATED:20190905T170951 SUMMARY:Grant S. Murphy, Ph.D. LOCATION:CCB Auditorium (1303) DESCRIPTION:“Ex Vivo Metabolism: Novel Enzyme Cascades to Synthesize Active Pharmaceuti cal Ingredients”\nEnzymes are exceptional catalysts with unparalleled selec tivity and rate enhancement. In many cases, enzymes also offer significant advantages over traditional catalysts with respect to cost, safety, and env ironmental impact. Due to these properties, the use of enzymes as biocataly sts in industrial settings has grown dramatically. Central to the growth of biocatalysis as a chemistry tool has been the ability to create novel enzy me functions and properties using protein design and engineering. The field s of biocatalysis and protein engineering have matured to the point where t he identification of new enzyme activity and further engineering of an enzy me for synthetic chemistry purposes have become almost routine. These advan cements have made it practical to consider moving beyond the engineering of a single enzyme and to consider the invention of entirely novel multi-enzy me cascades not found in nature to synthesize compounds not found in nature . These novel pathways could be considered ex vivo metabolic processes; enz yme cascades created and occurring outside the confines of living systems. For the past three years, the Merck Biocatalysis and Protein Engineering gr oup has focused on the creation of ex vivo enzyme cascades to synthesize Me rck drug compounds. This talk will highlight recent examples of our group’s successful efforts to engineer novel enzyme cascades to synthesize Merck c ompounds from simple starting materials.\n~Coffee/tea will be served prior to lecture~\n X-ALT-DESC;FMTTYPE=text/html:
“Ex Vivo Metabolism: N ovel Enzyme Cascades to Synthesize Active Pharmaceutical Ingredients”
Enzymes are exceptional catalysts wi th unparalleled selectivity and rate enhancement. In many cases, enzymes al so offer significant advantages over traditional catalysts with respect to cost, safety, and environmental impact. Due to these properties, the use of enzymes as biocatalysts in industrial settings has grown dramatically. Cen tral to the growth of biocatalysis as a chemistry tool has been the ability to create novel enzyme functions and properties using protein design and e ngineering. The fields of biocatalysis and protein engineering have matured to the point where the identification of new enzyme activity and further e ngineering of an enzyme for synthetic chemistry purposes have become almost routine. These advancements have made it practical to consider moving beyo nd the engineering of a single enzyme and to consider the invention of enti rely novel multi-enzyme cascades not found in nature to synthesize compound s not found in nature. These novel pathways could be considered ex vivo met abolic processes; enzyme cascades created and occurring outside the confine s of living systems. For the past three years, the Merck Biocatalysis and P rotein Engineering group has focused on the creation of ex vivo enzyme casc ades to synthesize Merck drug compounds. This talk will highlight recent ex amples of our group’s successful efforts to engineer novel enzyme cascades to synthesize Merck compounds from simple starting materials.
~Coffee/tea will be served prior to lecture~
X-EXTRAINFO:Hosted by Professor Sagar Khare DTSTAMP:20240328T194301 DTSTART:20191029T150000 DTEND:20191029T160000 SEQUENCE:0 TRANSP:OPAQUE END:VEVENT END:VCALENDAR